Ischemic stroke is a leading cause of permanent disability and mortality and there is an urgent need for adjunctive therapies for concurrent administration with existing clot-busting (tissue plasminogen activator, tPA) and endovascular clot removal (thrombectomy) treatments. This evidence concerns the gene PLAT and ischemic stroke.